The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
Open accessAbstract
Introduction: Hereditary transthyretin-mediated amyloidosis (ATTRv; v for variant) is an underdiagnosed, progressive, and fatal multisystemic disease with a heterogenous clinical phenotype that is caused by TTR gene mutations that destabilize the TTR protein, resulting in its misfolding, aggregation, and deposition in tissues throughout the body.Areas covered: Inotersen, an antisense oligonucleotide inhibitor, was recently approved in the United States and Europe for the treatment of the polyneuropathy of ATTRv based on the positive results obtained in the pivotal phase 3 trial, NEURO-TTR. This review will discuss the mechanism of action of inotersen and its pharmacology, clinical efficacy, and safety and tolerability. A PubMed search using the terms ‘inotersen,’ ‘AG10,’ ‘antisense oligonucleotide,’ ‘hereditary transthyretin amyloidosis,’ ‘familial amyloid polyneuropathy,’ and ‘familial amyloid cardiomyopathy’ was performed, and the results were screened for the most relevant English language publications. The bibliographies of all retrieved articles were manually searched to identify additional studies of relevance.Expert opinion: Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy. Inotersen is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
From CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis (2021) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationTafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Self-citationGuideline of transthyretin-related hereditary amyloidosis for clinicians
Ando, Y., Coelho, T., Berk, J. L., Cruz, M. W., Ericzon, B.-G., Ikeda, S.-I., Lewis, W. D., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 719
Self-citationRepurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Self-citationHolmgren, G., Steen, L., Suhr, O., Ericzon, B.-G., Groth, C.-G., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)93127-m · Cited by 579
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., Fontana, M., Moon, J. C., Pinzani, M., Gillmore, J. D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504942 · Cited by 378
Coelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Ericzon, B.-G., Wilczek, H. E., Larsson, M., Wijayatunga, P., Stangou, A., Pena, J. R., Furtado, E., Barroso, E., Daniel, J., Samuel, D., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000574 · Cited by 314
Research works printed but not linked: 7
- Coelho T, 2016, A guide to transthyretin amyloidosis
- Gertz MA., 2017, Am J Manag Care, 23, S107
- 2018, Vyndaqel [summary of product characteristics]
- 2019, Vyndaqel [prescribing information]
- 2018, Tegsedi [prescribing information]
- 2018, Tegsedi [summary of product characteristics]
- Brannagan T, 2018, Presented at: American Society of Hematology Annual Meeting and Exposition
Cited by
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Metadata
- Authors
- Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L.
- Affiliations
- Mayo Clinic (US)
- Hospital Israelita Albert Einstein (BR)
- Neuromuscular Diseases Unit, Federal University of Rio de Janeiro, University Hospital, Rio de Janeiro, Brazil
- Oregon Health & Science University (US)
- University of Pennsylvania (US)
- University College London (GB)
- Policlinico San Matteo Fondazione (IT)
- Corresponding author
- Gertz, Morie A.
- ORCID
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2019-07-03
- Volume
- 12
- Issue
- 8
- Pages
- 701-711
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2955523092
- Cited by
- 38
- References
- 50
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 8 · 2023: 9 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 1
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Funders
- ApotheCom (01)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- inotersen, hereditary transthyretin amyloidosis, polyneuropathy, antisense oligonucleotides, familial amyloid cardiomyopathy, glomerulonephritis, thrombocytopenia, drug safety and tolerability
- MeSH terms
- Adult, Animals, Humans, Mutation, Oligonucleotides, Polyneuropathies, Prealbumin, Quality of Life, Oligodeoxyribonucleotides, Antisense, Amyloid Neuropathies, Familial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. https://app.cochat.ai/papers/10.1080/17512433.2019.1635008
- The paper
- Gertz, M. A., Scheinberg, M., Waddington-Cruz, M., Heitner, S. B., Karam, C., Drachman, B., Khella, S., Whelan, C., & Obici, L. (2019). Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2019.1635008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.